Clinical Impact of Pre-Existing Autoantibodies in Patients With SCLC Treated With Immune Checkpoint Inhibitor: A Multicenter Prospective Observational Study
Yuki Sato(Goethe University Frankfurt), Keisuke Tomii(Kobe City Medical Center General Hospital), Hirotaka Matsumoto(Hyogo Prefectural Amagasaki General Medical Center), Takahiro Masuda(Jichi Medical University), Kotoko Miyoshi(Shinko Hospital), Akito Hata, Yoko Kida(Kobe City Nishi-Kobe Medical Center), Hisanori Amimoto(Kobe City Medical Center West Hospital), Kojiro Otsuka(Shinko Hospital), Satoru Fujiwara(Kobe City Medical Center General Hospital)
Cited by 7
Related Papers
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
|American Journal of Physiology-Renal Physiology|2013|481
Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|365
Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia
|American Journal of Physiology-Renal Physiology|2013|308
Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice
|American Journal of Physiology-Renal Physiology|2012|158
Osmotic diuresis by SGLT2 inhibition stimulates vasopressin‐induced water reabsorption to maintain body fluid volume
|Physiological Reports|2020|135